I'm looking at a slow gradual increase.... If you remembered this article from August PRWEB
First advance orders for new MPDD devices are now being received from physicians and the Company is anticipating very strong demand in 2013 after worldwide distribution release. The MPDD devices will initially be marketed under the therapeutic label and later will be marketed under the diagnostic label with an additional FDA 510k. MPDD devices will be priced between $12,000.00 and $20,000.00 depending on the package level of training and education purchased by physicians and health organizations. The Company will market to pain physicians, primary physicians, Internists, sports medicine physicians and physical therapists to name just a few in the significant market for the MPDD device. The MPDD device is only the first of several products which the Company will market in the months and years ahead as the Company is extremely interested in the promising field of bioelectronics and non-opioid treatments of pain.
Shareholders are the most important asset to EPGL Med. The Company is committed to growing significant market capitalization and shareholder returns. To this end, the Company is now taking requisite steps to resume full reporting status and move up to OTCBB in the near future. New financial statements and filings will begin by end of year 2012.
The MPDD devices will initially be marketed under the therapeutic label and later will be marketed under the diagnostic label with an additional FDA 510k.
Interesting... So you want to start at THERAPEUTIC LABEL and then later market it under DIAGNOSTIC LABEL.... so what exactly can EPGL do in 2013... 5 days and I will finally see your OTC reporting...This game is definitely not over..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
